Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.
Humans
COVID-19 Vaccines
/ immunology
mRNA Vaccines
/ immunology
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Memory B Cells
/ immunology
COVID-19
/ prevention & control
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Lymphoid Tissue
/ immunology
Lab-On-A-Chip Devices
Vaccines, Synthetic
/ immunology
RNA, Messenger
/ genetics
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Liposomes
Nanoparticles
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
14
02
2024
revised:
26
06
2024
accepted:
12
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
ppublish
Résumé
Predicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion. Features of lymphoid tissue, including the formation of activated CD4+ T cell/B cell clusters and the emigration of matured plasmablasts, were recapitulated in the LO chip. Importantly, myeloid cells were competent at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of responses to mRNA vaccines. Comparison of on-chip responses to Wuhan monovalent and Wuhan/Omicron bivalent mRNA vaccine boosts showed equivalent induction of Omicron neutralizing antibodies, pointing at immune imprinting as reported in vivo. The LO chip thus represents a versatile platform suited to the preclinical evaluation of vaccine-boosting strategies.
Identifiants
pubmed: 39240335
pii: 276956
doi: 10.1084/jem.20240289
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
mRNA Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Vaccines, Synthetic
0
RNA, Messenger
0
Lipid Nanoparticles
0
Liposomes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Emulate
ID : S-RD21002
Organisme : Pasteur COVID-19 RP call
Organisme : Fondation de France
ID : PR-166156
Organisme : Institut Pasteur
ID : PFR7
Organisme : French Agency for AIDS and Emerging Diseases Research (ANRS-MIE)
ID : ECTZ213626
Organisme : Institut Carnot Pasteur Microbe & Santé
Informations de copyright
© 2024 Jeger-Madiot et al.